drugset / Trial / NCT02229422
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
NaSingle-groupOpen-labelTreatment
Summary
We hypothesize that GA101 - Obinutuzumab in combination with HDMP is well tolerated and will induce similar if not higher response rates than the ones observed in Rituximab plus HDMP studies (Castro et al., 2009, Castro et al., 2008).
Timeline
- Start
- 2014-09
- Primary completion
- 2025-10-30
- Completion
- 2025-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylprednisolone | Other / unclassified | 1000 mg/m2 | Intravenous |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |